- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07951242
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of a Children's Fiber Blend on Digestive Health and Gut Microbiome Composition in Children
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LOAM Kids Gut Starter Fiber Formula on Digestive Health and Gut Microbiome Composition in Children
This study evaluates the impact of a fiber blend supplement on gastrointestinal symptoms and the gut microbiome in children aged 3-6 with a history or irregular stooling.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Bryce Jarman
- Número de teléfono: 323-325-1327
- Correo electrónico: bryce@loamscience.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female child, aged 3-6 years (inclusive) at the time of enrollment.
- Caregiver reports the child consumes few vegetables, whole fruit, whole grains, or legumes per week (fewer than two per day on average), consistent with this study's operational definition of low dietary fiber intake.
- Caregiver reports infrequent or difficult bowel movements (constipation) in the child over the past four weeks
- Caregiver reports the child has experienced excess gas, or bloating, over the past four weeks
- Caregiver is willing and able to administer the study product to the child once daily with a meal for 4 weeks, complete digital questionnaires at Baseline, Weeks 1, 2, 3, and End of Study on behalf of the enrolled child, and to facilitate at-home microbiome stool sample collection at Baseline and End of Study and return samples per provided instructions.
- Child is generally healthy, without any acute or chronic condition that would preclude safe participation as determined by caregiver report.
- Caregiver is willing to maintain the child's current diet, sleep patterns, and activity levels throughout the study duration, and to avoid introducing new fiber supplements or probiotic/prebiotic products during the study period.
- Caregiver and child reside in the United States.
- Caregiver is willing and able to provide informed consent; child assent will be obtained where age-appropriate and consistent with IRB requirements.
Exclusion Criteria:
- Known milk allergy, dairy allergy, lactose intolerance, or any known sensitivity to milk-derived products. (The study product's active formulation contains a milk allergen.)
- Child is currently breastfeeding.
- Known allergy or sensitivity to any component of the study product.
- Currently receiving anticoagulant or antiplatelet medications (e.g., warfarin), due to potential interaction with Vitamin K2 contained in the study product.
- Diagnosis of, or current treatment for, any gastrointestinal disease or disorder, including but not limited to: inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, celiac disease, or diagnosed functional gastrointestinal disorders requiring medical management.
- Use of any prescription or over-the-counter laxative, stool softener, antidiarrheal medication, or fiber supplement on a regular basis (≥3 times per week) in the 4 weeks prior to enrollment, or intent to use during the study.
- Use of oral antibiotics or antifungals within 4 weeks prior to enrollment, or anticipated use during the study period.
- Use of any probiotic or prebiotic supplement (other than those naturally occurring in diet) in the 4 weeks prior to enrollment, or intent to use during the study.
- Significant acute illness, including fever, acute gastrointestinal infection, or other acute medical condition at the time of enrollment, or any chronic medical condition, developmental condition, or disability that, in the caregiver's judgment or per clinical guidance, would prevent the child from safely adhering to the study protocol.
- Any planned surgical procedure during the 4-week study period.
- Participation in another research study currently or within the past 30 days, or planned participation in any other research study during this study's duration.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
|
Color and taste matched placebo. |
|
Experimental: Fiber Blend
|
This fiber blend contains a blend of Bifidogenic fibers and HMOs |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Stool Frequency
Periodo de tiempo: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Caregiver reported number of bowel movements per week |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
|
Stool Consistency
Periodo de tiempo: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Caregiver reported stool consistency using the pediatric-adapted Bristol Stool Scale (one-seven, with one indicating hard lumpy stools and seven indicating soft liquid stools) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
|
Digestive Comfort
Periodo de tiempo: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Digestive comfort assessed using a visual analog scale (one-five, with one being very bad and five being very good) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Microbiome Composition
Periodo de tiempo: Baseline, End of Study (Week 4)
|
Determined using shotgun metagenomic sequencing |
Baseline, End of Study (Week 4)
|
|
Gas and Bloating
Periodo de tiempo: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Gas and bloating assessed using a visual analog scale (one-five, with one being never bloated and five being always bloated) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- LOA005
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Data is proprietary
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .